L3VLUP
ProSign in

GSK in the 13F filings

GSK PLC · CUSIP 37733W204

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Quarter end
30 Jun 2026
the date the book describes
Filed
27 Oct 2026
latest of these filings; the earliest 3 Aug 2026
Managers listing it
25
at least, of 95 tracked, among listed positions
Comparable managers
91
filed both Q1 2026 and Q2 2026; 8 listed it in both
Shares listed
146,346,369
combined, among listed positions
Reported value
$7.7bn
combined, at the quarter end

AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.

Among the 91 comparable managers: 15 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -20,737,438.

Managers listing GSK in Q2 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

25 of 25 holders

ActionFiling
Fidelity (FMR LLC)64,961,641$3.4bn0.15%Trimmed-2,700,00513 Aug 2026 (the filing on sec.gov)
Dodge & Cox48,197,514$2.5bn1.32%Trimmed-10,465,46013 Aug 2026 (the filing on sec.gov)
Wellington Management Group LLP11,396,249$597m0.10%Trimmed-321,36414 Aug 2026 (the filing on sec.gov)
T. Rowe Price Associates Inc6,923,642$363munder 0.1%Trimmed-399,19114 Aug 2026 (the filing on sec.gov)
Acadian Asset Management LLC6,660,434$349m0.41%Trimmed-5,136,65113 Aug 2026 (the filing on sec.gov)
Point72 Asset Management LP2,652,881$139m0.15%Newnew14 Aug 2026 (the filing on sec.gov)
Arrowstreet Capital LP1,633,029$86munder 0.1%Added+11,63213 Aug 2026 (the filing on sec.gov)
D. E. Shaw & Co.1,019,449$53munder 0.1%Newnew14 Aug 2026 (the filing on sec.gov)
Jane Street Group LLC551,413$29munder 0.1%Trimmed-109,98614 Aug 2026 (the filing on sec.gov)
Bridgewater Associates LP504,171$26m0.11%Trimmed-194,49514 Aug 2026 (the filing on sec.gov)
Walleye Capital LLC402,472$21m0.08%Added+29,3763 Aug 2026 (the filing on sec.gov)
AQR Capital Management LLC346,157$18munder 0.1%Added+63,03414 Aug 2026 (the filing on sec.gov)
MFS Investment Management319,805$17munder 0.1%Added+107,4393 Aug 2026 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC199,265$10munder 0.1%Newnew14 Aug 2026 (the filing on sec.gov)
Citadel Advisors LLC151,573$7.9munder 0.1%Newnew2 Sep 2026 (the filing on sec.gov)
Quantbot Technologies LP128,286$6.7m0.27%Newnew12 Aug 2026 (the filing on sec.gov)
Neuberger Berman Group LLC74,270$3.9munder 0.1%Added+6,88227 Oct 2026 (the filing on sec.gov)
Two Sigma Investments LP70,993$3.7munder 0.1%Newnew14 Aug 2026 (the filing on sec.gov)
Squarepoint Ops LLC57,963$3.0munder 0.1%Trimmed-4,74814 Aug 2026 (the filing on sec.gov)
Verition Fund Management LLC41,337$2.2munder 0.1%Held014 Aug 2026 (the filing on sec.gov)
Marshall Wace LLP23,174$1.2munder 0.1%Newnew13 Aug 2026 (the filing on sec.gov)
Winton Group Ltd11,500$603kunder 0.1%Newnew7 Aug 2026 (the filing on sec.gov)
AllianceBernstein LP8,302$458kunder 0.1%Added+4,05914 Aug 2026 (the filing on sec.gov)
Susquehanna International Group LLP5,991$314kunder 0.1%Trimmed-51,45714 Aug 2026 (the filing on sec.gov)
Invesco Ltd4,858$255kunder 0.1%Added+16814 Aug 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2026 to Q2 2026, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (8)

Exited (3)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
10 in Q3 2024 to 11 in Q2 2026

Tracked managers listing it, at least.

051015202023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GSK by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20221$19mn.a.n.a.
Q3 202218$3.9bnn.a.n.a.
Q4 202218$4.9bnn.a.n.a.
Q1 202313$4.4bnn.a.n.a.
Q2 202313$4.3bnn.a.n.a.
Q3 202316$4.5bnn.a.n.a.
Q4 202313$4.5bn67
Q1 202413$5.3bn57
Q2 202410$4.6bn64
Q3 202410$4.9bn63
Q4 202413$4.9bn112
Q1 202511$6.3bn76
Q2 202510$6.2bn83
Q3 202511$7.5bn65
Q4 202511$8.8bn1513
Q1 20269$9.1bn919
Q2 202611$7.5bn1512

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GSK, latest filings →Back to the 13F Explorer →